Shionogi Highlights COVID-19 and Antibiotic Pipeline Progress at IDWeek 2026
Event summary
- Shionogi Inc. will present 20+ data sets across its infectious disease portfolio at IDWeek 2026 (Oct 21-24).
- Key highlights include FDA approval of XOCOVA (ensitrelvir) and sNDA submission for pediatric use of Fetroja (cefiderocol).
- Presentations cover COVID-19 antiviral research and Gram-negative antibiotic programs, including SENTRY surveillance data.
- Preclinical research on xeruborbactam, a beta-lactamase inhibitor from Qpex Biopharma, will also be featured.
The big picture
Shionogi's IDWeek 2026 presentations underscore its focus on combating antimicrobial resistance and COVID-19. The company's strategic emphasis on both marketed products and investigational therapies positions it as a key player in the infectious disease space. Its partnerships with global health organizations further highlight its commitment to expanding access to critical treatments.
What we're watching
- Regulatory Momentum
- Whether Shionogi can leverage the FDA approval of XOCOVA to expand its COVID-19 antiviral market share.
- Pipeline Execution
- The pace at which Shionogi advances its Gram-negative antibiotic programs through clinical trials.
- Partnership Strategy
- How collaborations with GARDP and CHAI will impact global access to Shionogi's antimicrobial treatments.
Related topics